ADMA BIOLOGICS, INC.

source: coverage-next-full ticker: ADMA step: 01 title: Business Model & Overview created: 2026-06-03

Step 01 — Business Model & Overview: ADMA Biologics, Inc.

Key Findings

Net positive for long-term thesis, conditional on the channel-stuffing allegation being incorrect. ADMA is a vertically integrated specialty biopharmaceutical company with a defensible niche: manufacturing RSV-enriched immune globulin (ASCENIV) for a patient population with no direct competitor. The business model has compelling economics — plasma is collected at ADMA-owned centers, fractionated at its Boca Raton plant, and sold directly to specialty distributors. However, the model's vulnerability is concentration: ~71% of FY2025 revenue came from one product (ASCENIV), and the manufacturing supply chain runs through a single fractionation facility [S1][S3].

Implications for Thesis and Valuation

• ASCENIV's differentiated biology (RSV-enriched plasma pool) creates a premium pricing position not available to commodity IVIG producers. This is the moat worth pricing.
• BIVIGAM is increasingly a drag: it competes with ~5 well-capitalized players (CSL, Grifols, Takeda, Octapharma, Baxter) on price alone [S5]. No pricing power.
• The vertically integrated model (plasma collection → fractionation → commercial) is capital-intensive (10 plasma collection centers, one fractionation plant) but creates a margin flywheel as volumes scale.
• Nabi-HB (hepatitis B IGIV) is a niche product that contributes modestly.

Objective

Map ADMA's business model, value-chain architecture, and revenue layer structure to identify where value is created and where the key risks reside.

Narrative Analysis

ADMA Biologics operates at the intersection of plasma collection, biologics manufacturing, and specialty pharmaceutical commercialization. Unlike most specialty pharma companies that outsource manufacturing, ADMA controls every step of its supply chain — from sourcing plasma at its own collection centers to fractionating and purifying it at its FDA-licensed manufacturing facility in Boca Raton, FL [S1][S3].

The three-product portfolio:

1. ASCENIV (immune globulin intravenous 10%, caprylate chromatography purified): FDA-approved April 2019 for primary humoral immunodeficiency (PI). The key differentiator is ADMA's plasma sourcing protocol, which selects for donors with documented high RSV antibody titers. The resulting product has demonstrably higher RSV neutralizing antibody content than standard IVIG. In the pivotal trial, ASCENIV reduced serious bacterial infections in PI patients and separately demonstrated a reduction in respiratory infection rate from 2.1 to 0.9 per year for PI patients with recurrent lower respiratory infections [S5]. This narrow but validated clinical differentiation drives premium pricing (estimated $90–120K/patient-year vs. $40–60K for standard IVIG). Management guided for ASCENIV at $363M in FY2025 (~71% of total revenue) [S3].

2. BIVIGAM (immune globulin intravenous 10%, caprylate chromatography purified): FDA-approved 2012 for PI. Unlike ASCENIV, BIVIGAM uses a standard plasma pool with no RSV enrichment. It competes head-to-head with Gamunex-C (Grifols), Privigen (CSL Behring), Octagam (Octapharma), and Gammagard (Takeda) — all better-capitalized manufacturers [S5]. BIVIGAM has no pricing power and serves primarily as a base-load utilization vehicle for ADMA's manufacturing plant. Q1 2026 saw BIVIGAM revenue collapse ~54% YoY, suggesting price erosion and/or volume loss is accelerating [S4].

3. Nabi-HB (hepatitis B immune globulin): A legacy product used to prevent HepB recurrence post-liver transplant and after exposure. A small, stable niche product contributing approximately $50–70M annually.

Value chain architecture:

Plasma Donors → ADMA BioCenters (10 centers) → Boca Raton Fractionation Facility
→ ASCENIV / BIVIGAM / Nabi-HB → Specialty Distributors → Specialty Pharmacies → PI Patients

ADMA operates 10 FDA-licensed plasma collection centers under the ADMA BioCenters brand [S3]. These centers collect Source Plasma from paid donors. A critical operational fact: for ASCENIV, ADMA can only use plasma from donors who have documented high RSV antibody titers. This requires either pre-screening (costlier) or a "re-bleed" approach where donors with a history of RSV infection are tracked. This supply constraint caps ASCENIV production volume — it cannot simply scale by buying third-party plasma.

The fractionation facility in Boca Raton is the single-point-of-failure in the supply chain. All products flow through it. This is both a competitive barrier (plasma fractionation requires a FDA BLA and cGMP manufacturing certification that takes 7–12 years to establish) and a concentration risk (a manufacturing shutdown would be catastrophic) [S5].

Evidence and Sources

Revenue and margin data from SEC XBRL and StockAnalysis annual financials [S1][S6]. Product descriptions from 10-K FY2025 business section [S3]. Competitive context from industry research [S5].

Assumption Register Updates

Tables and Calculations

Revenue Architecture (FY2025)

Segment estimates derived from management commentary and 10-K disclosures [S3]

Value-Chain Layer Map

Open Questions and Data Gaps

1. What is BIVIGAM's trajectory — will ADMA defend it or allow it to wind down?
2. ASCENIV production capacity constraints: how much can output grow given RSV-seropositive plasma supply limits?
3. Is Nabi-HB growing, stable, or declining in unit volume?

Next-Step Dependencies

Step 02 should use the peer universe list in this step and the product-market mapping to assess Porter's five forces for plasma-derived biologics.

Source Index

source: coverage-next-full ticker: ADMA step: 04 title: Financial Quality & Adversarial Sweep created: 2026-06-03

Step 04 — Financial Quality & Adversarial Sweep: ADMA Biologics, Inc.

Key Findings

NET NEGATIVE — material red flags require investigation. The Adversarial Sweep surfaces the Culper Research short report as the dominant concern. The DSO expansion from ~43 days (FY2024) to ~113 days (FY2025) is real, large, and unexplained by management to the market's satisfaction. Multiple securities fraud investigation law firms launched probes [S7]. Q1 2026's $114.5M revenue (vs. $142.7M expected) and guidance cut provided partial validation of the concern [S4]. The financial quality assessment must treat FY2025 revenue as potentially overstated pending investigation, and the analytical base case should use FY2024 as the more reliable baseline.

Setting aside the controversy, underlying financial quality is strong: GAAP-to-cash conversion, low D&A (asset-light fractionation through Q4 2025 CapEx), minimal goodwill, and no evidence of aggressive non-cash accounting [S1][S6].

Implications for Thesis and Valuation

• The FY2025 reported $510M revenue should be treated as a high-confidence floor for the bull case and a questioned number in the bear case (channel stuffing would mean some FY2025 revenue was "borrowed" from FY2026).
• The Q1 2026 AR collection progress ($158M → $136M, a $22M reduction) is a positive data point — distributors are paying down their balances, which is inconsistent with permanent channel stuffing but consistent with a Q4 2025 end-of-year push followed by normal collection.
• If the channel stuffing allegation is false, the stock trades at ~11x trailing P/E on $146.9M net income — a compelling valuation for a profitable, growing specialty pharma.

Objective

Assess the quality of ADMA's reported financials through statement adjustments and an adversarial research sweep covering short-seller reports, investigations, and regulatory concerns.

Narrative Analysis

Statement quality assessment:

Revenue recognition uses ASC 606 (contracts with customers). ADMA sells to specialty distributors under contracts with standard commercial terms. Revenue is recognized when control transfers to the distributor — typically when product ships [S3]. Under this model, revenue can be pulled forward by shipping more product near quarter-end than the distributor would normally order. The key evidence of this:

• FY2025 accounts receivable: $158.4M vs. $50.0M at FY2024 year-end — a $108.4M increase [S1]
• FY2025 revenue growth: $83.7M (+19.6% YoY) [S1]
• The AR increase ($108M) was larger than the revenue increase ($84M), meaning ADMA collected less cash from revenue in FY2025 than in FY2024. This is anomalous.
• DSO calculation: $158.4M / $510.2M × 365 = 113.4 days. For context, the prior year (FY2024) DSO was $50.0M / $426.5M × 365 = 42.8 days — essentially unchanged from FY2023 (~38.7 days). The jump from 43 to 113 is a 2.6x increase in one year [S1].

Management has not provided a satisfactory public explanation (per Tavily research). Possible legitimate explanations: (1) Revised distributor payment terms extended from standard net-30 to net-60 or net-90; (2) A large new distributor relationship with different payment timing; (3) Specialty pharmacy reimbursement timing shifts. None of these have been confirmed [S4].

Adversarial Research Sweep:

Short-seller report — Culper Research (March 26, 2026): Culper alleged that ADMA "channel stuffed" distributors with ASCENIV inventory in Q3 and Q4 2025 to manufacture revenue growth metrics that would sustain management's >$635M FY2026 guidance. Key allegations:

1. DSO jumped from 43 to 113 days — product shipped but not yet paid
2. Management guided for >$635M in FY2026 while internally knowing distributor inventory was elevated
3. CEO and Chairman were selling stock actively in 2025 while guidance was set at unsustainable levels
4. BIVIGAM pricing was under extreme pressure but not communicated transparently The stock fell ~28% in two sessions following the report [S7].

Securities fraud investigations: Following the Q1 2026 earnings miss and guidance cut (May 6, 2026), multiple securities plaintiff law firms (Bernstein Liebhard, etc.) announced investigations into potential securities fraud claims on behalf of ADMA shareholders. These investigations are in their early stages and no formal complaint has been filed, to Tavily's knowledge as of June 2026 [S7].

Regulatory concerns (product quality): No FDA warning letters or consent decrees found for ADMA's Boca Raton manufacturing facility as of 2026 [S2][S3]. ADMA received FDA approval for a yield enhancement process in FY2025, which contributed to the gross margin step-up in Q4 2025 / Q1 2026 (from ~53% to 64–70%). This explains some of the gross margin improvement but does not address the AR build.

Management credibility: CEO Adam Grossman's credibility is at a nadir post-Culper/guidance-cut. However, the Grossman family (Adam + Jerrold) founded the company in 2004 and has significant skin in the game. Jerrold Grossman bought 12,500 shares at $8.01 in May 2026, post-selloff [S8]. If the channel-stuffing allegations were accurate, buying at these prices would be irrational.

Positive financial quality markers:

1. Minimal goodwill ($3.5M) — no acquisition overhang [S6]
2. Low D&A relative to EBITDA — manufacturing is carried at book value, not inflated
3. R&D is minimal ($4.8M FY2025) — company is not burning cash on unproven pipeline [S6]
4. CapEx is modest ($14.4M FY2025) — the fractionation facility is already built [S6]
5. Inventory ($206.5M at FY2025) is high but reflects manufacturing cycle times — plasma to finished product takes 9–12 months [S3]

Assumption Register Updates

Tables and Calculations

DSO Analysis

Q1 2026 annualized AR/Rev would overstate DSO — on a TTM basis: $135.9M / $509.9M TTM × 365 = ~97 days. AR declining from FY2025's $158.4M is evidence of ongoing collection.

Key Financial Quality Metrics

Adversarial Sweep Summary

Open Questions and Data Gaps

1. What are ADMA's payment terms with specialty distributors? Any changes in FY2025?
2. What is the current distributor inventory level for ASCENIV? Management should address this on Q2 2026 call.
3. Will Q2 2026 AR continue to normalize?

Source Index